Cancer risk with JAK inhibitors versus TNF inhibitors

被引：0
|
作者：
Thorley, Jennifer
机构：
来源：
LANCET RHEUMATOLOGY | 2023年 / 5卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：e252 / e252
页数：1
相关论文
共 50 条
  • [1] JAK Inhibitors and Risk of Cancer
    Gouverneur, Amandine
    Avouac, Jerome
    Prati, Clement
    Cracowski, Jean-Luc
    Schaeverbeke, Thierry
    Pariente, Antoine
    Truchetet, Marie-Elise
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4400 - 4401
  • [2] Tofacitinib increases risk of MACE and cancer versus TNF inhibitors
    Reactions Weekly, 2022, 1893 (1) : 12 - 12
  • [3] Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study
    Se Rim Choi
    Anna Shin
    You-Jung Ha
    Yun Jong Lee
    Eun Bong Lee
    Eun Ha Kang
    Arthritis Research & Therapy, 25
  • [4] Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study
    Choi, Se Rim
    Shin, Anna
    Ha, You-Jung
    Lee, Yun Jong
    Lee, Eun Bong
    Kang, Eun Ha
    ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
  • [5] Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis
    Choi, Se Rim
    Shin, Anna
    Ha, You-Jung
    Lee, Yun Jong
    Lee, Eun Bong
    Kang, Eun Ha
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 589 - 590
  • [6] RISK OF INFECTIONS BETWEEN JAK INHIBITORS AND TNF INHIBITORS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS
    Choi, S. R.
    Shin, A.
    Ha, Y. J.
    Lee, Y. J.
    Lee, E. B.
    Kang, E. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 716 - 716
  • [7] THE COMPARISON OF MALIGNANCY RISK BETWEEN JAK INHIBITORS AND TNF INHIBITORS IN MULTICENTER COHORT STUDY
    Uchida, T.
    Iwamoto, N.
    Fukui, S.
    Morimoto, S.
    Aramaki, T.
    Shomura, F.
    Aratake, K.
    Eguchi, K.
    Ueki, Y.
    Kawakami, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 717 - 718
  • [8] Hunting uncertainties: JAK inhibitors and cancer risk
    Lee, Hsiu-Ming
    Chi, Huan-Ting
    Wei, James Cheng-Chung
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2024, 27 (02)
  • [9] Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis
    Zhao, Sizheng Steven
    Riley, David
    Hernandez, Gema
    Alam, Uazman
    CLINICAL THERAPEUTICS, 2025, 47 (04) : 293 - 297
  • [10] No increased risk of cancer recurrence with TNF inhibitors
    Reactions Weekly, 2018, 1718 (1) : 7 - 7
12345